However, palbociclib only showed a modest effect (20% patients had tumor shrinkage at 8 weeks) as monotherapy in advanced acral melanoma with CDK4 pathway gene aberrations in a phase II clinical study [112]. This evidence concerns the gene CDK4 and neoplasm.